Roche Working "Day and Night" to Boost Covid-19 Treatment Production - CEO Schwan

The transcript discusses the impact of COVID-19 on medical treatments, highlighting the recovery trends post-lockdown. It examines the market impact of biosimilars and the growth of newly launched medicines. The discussion extends to the approval and production challenges of COVID-19 antibody treatments, emphasizing the need for cooperation in the pharmaceutical industry. Finally, it analyzes the EU's slower vaccine distribution compared to the UK and USA, focusing on production bottlenecks and the need for increased capacities.

What is the significance of the newly launched medicines in the context of overall sales?

How is the company planning to address the demand for COVID-19 antibody treatments?

What lessons can be learned from the EU's vaccine rollout compared to the UK and USA?